Tumour necrosis factor-beta

Drug Profile

Tumour necrosis factor-beta

Alternative Names: Lymphotoxin

Latest Information Update: 14 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Developer Kanegafuchi Chemicals
  • Class Antihyperglycaemics; Antineoplastics; Antivirals; Cytokines; Tumour necrosis factors
  • Mechanism of Action Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Type 1 diabetes mellitus

Most Recent Events

  • 17 Jul 1998 No-Development-Reported for Type-1 diabetes mellitus in Japan (Intraperitoneal)
  • 23 Jun 1998 Commercial data has been reviewed by Fujisawa
  • 03 Oct 1995 An in vivo study has been added to the Diabetes pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top